GRM5 and Parkinson disease: An initial clinical trial with mGlu5 NAM mavoglurant showed that inhibition of mGlu5 is effective in reducing LID in PD patients [40] and dipraglurant has successfully completed a Phase IIa trial in PD-LID [41].